pocketful logo
Dr Agarwals Eye Hospital Ltd logo

Dr Agarwals Eye Hospital Ltd

NSE: BSE: 526783

4771.45

(-0.34%)

Mon, 23 Feb 2026, 02:43 pm

Dr Agarwals Eye Hospital News

Dr. Agarwal's Eye Hospital Q3 Net Profit Jumps 63%

Dr. Agarwal's Eye Hospital Limited reports strong Q3 performance with net profit rising to ₹170 million from ₹104 million year-on-year, marking significant growth in profitability.

03 Feb 2026

co actions results

Dr. Agarwal's Eye Hospital Declares Rs 3 Interim Dividend, Reports Quarterly Results

Dr. Agarwal's Eye Hospital Limited's Board of Directors approved unaudited financial results for the quarter and half-year ended September 30, 2025. The company declared an interim dividend of Rs 3 per equity share of Rs 10 each for financial year 2025-26, to be paid by November 29, 2025. The record date for dividend eligibility is November 7, 2025. The Board also approved a proposed scheme of amalgamation with Dr. Agarwal's Health Care Limited, subject to shareholder and regulatory approvals. Additionally, the company completed a preferential issue of 4,32,827 equity shares at Rs 5,270 per share to Dr. Agarwal's Health Care Limited, which was allotted on September 26, 2025. The proceeds from this preferential allotment are temporarily invested in debt mutual funds pending utilization. The company operates in a single segment of eye care related sales and services.

30 Oct 2025

corporate action

Dr. Agarwal's Eye Hospital Reports Strong Q2 Growth, Declares Interim Dividend

Dr. Agarwal's Eye Hospital announced Q2 results showing significant growth across key metrics. Net profit increased to 193.2 million rupees from 141.5 million rupees year-over-year. Revenue grew to 1.18 billion rupees compared to 1.02 billion rupees in the same period last year. EBITDA rose to 401.1 million rupees from 299 million rupees, with EBITDA margin improving to 34.07% from 29.26%. The company recommended an interim dividend of 3 rupees per share.

30 Oct 2025

corporate action

Dr. Agarwal's Eye Hospital Approves Merger with Parent Company and Preferential Share Allotment

Dr. Agarwal's Eye Hospital Limited's Board approved a merger scheme with Dr. Agarwal's Health Care Limited through amalgamation by absorption. Under the arrangement, AHCL will issue 23 equity shares for every 2 shares held by the Company's shareholders. The Company will also issue 1,32,827 equity shares to AHCL at ₹5,270 per share through preferential allotment, increasing AHCL's stake from 71.90% to 72.67%. Both companies operate in the eye care hospital business. The merger aims to achieve operational efficiencies, streamlined capital allocation, simplified governance, and shareholder value creation. AHCL had disclosed this merger intention in its IPO prospectus when it listed in February 2025. The Company scheduled its 31st Annual General Meeting for September 24, 2025. All transactions require statutory and regulatory approvals including from stock exchanges, SEBI, shareholders, creditors, and the National Company Law Tribunal.

27 Aug 2025

corporate action

Dr. Agarwal's Eye Hospital Reports 23% Growth in Q1 Net Profit

Dr. Agarwal's Eye Hospital reported a net profit of 173 million rupees for Q1, representing growth from 141 million rupees in the same period last year. The company's revenue increased to 1.17 billion rupees compared to 1 billion rupees year-over-year. Both profit and revenue metrics showed positive year-over-year growth during the quarter.

12 Aug 2025

earnings

Showing 15 of 9
Rows per page:

Market Current News

AU Small Finance Bank Limited logo

AU Small Finance Bank Limited

AU Small Finance Bank Clarifies Haryana De-Empanelment

AU Small Finance Bank addresses media reports on Haryana government de-empanelment, clarifies transaction details involving ₹47 crores, and reports deposit reduction from ₹735 crores to ₹538 crores.

22 Feb 2026

stocks

COFORGE LIMITED logo

COFORGE LIMITED

Coforge Gets NSE Sustainability Rating of 76 for FY2025

Coforge Limited receives NSE sustainability rating of 76 for FY2025, marking an 8-point improvement from previous year. Rating assigned independently by NSE subsidiary.

22 Feb 2026

stocks

Krsnaa Diagnostics Limited logo

Krsnaa Diagnostics Limited

Krsnaa Diagnostics Re-appoints Executive Chairman

Krsnaa Diagnostics board approves re-appointment of Mr. Rajendra Mutha as Executive Chairman for five consecutive years from April 26, 2026, subject to shareholder approval through postal ballot.

22 Feb 2026

stocks

IFGL Refractories Limited logo

IFGL Refractories Limited

IFGL Refractories Q3 FY26 Results Show Mixed Performance

IFGL Refractories reported 23% YoY consolidated revenue growth to INR 470 crores in Q3 FY26, though EBITDA margins compressed to 5.3% due to higher employee costs and product mix changes.

22 Feb 2026

co actions results

SUDARSHAN PHARMA INDUSTRIES LI logo

SUDARSHAN PHARMA INDUSTRIES LI

Sudarshan Pharma Faces GST Inspection Operation

Sudarshan Pharma Industries informed exchanges about GST inspection, search and seizure operation that commenced at its registered office on February 21, 2026, with business operations continuing normally.

22 Feb 2026

stocks

Showing 15 of 86771
Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800